Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis
- 31 May 2005
- journal article
- Published by Elsevier BV in Atherosclerosis
- Vol. 180 (1), 113-118
- https://doi.org/10.1016/j.atherosclerosis.2004.11.004
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Angiopoietin‐1 inhibits endothelial permeability, neutrophil adherence and IL‐8 productionBritish Journal of Pharmacology, 2003
- Angiogenesis induced by advanced glycation end products and its prevention by cerivastatinThe FASEB Journal, 2002
- Suppression of Diabetic Retinopathy with Angiopoietin-1The American Journal of Pathology, 2002
- Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetesClinical Science, 2002
- Angiopoietin-1, Unlike Angiopoietin-2, Is Incorporated into the Extracellular Matrix via Its Linker Peptide RegionJournal of Biological Chemistry, 2001
- Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathyKidney International, 2000
- Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression CloningCell, 1996
- Carotid Artery Intima-Media Thickness in Elderly Patients With NIDDM and in Nondiabetic SubjectsStroke, 1996
- Microalbuminuria and endothelial dysfunction in essential hypertensionThe Lancet, 1994
- Diabetes and cardiovascular risk factors: the Framingham study.Cell Metabolism, 1979